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mol considering pain relief, pain intensity difference, patient’s
global treatment satisfaction and between intravenous paraceta-
mol and metamizole on pain scores and pain scores on coughing.
Intravenous paracetamol had safety proﬁle similar to placebo.
Adults treated with intravenous paracetamol had 9 times lower
risk of adverse events (RR = 0.11; 95%CI: 0.05–0.24) and 30
times lower risk of infusion site reactions (RR = 0.03; 95%CI:
0.01–0.16), comparing with propacetamol. CONCLUSIONS:
Intravenous paracetamol is an effective drug in postoperative pain
management in children and adults as superior to oral paraceta-
mol and placebo. Its efﬁcacy is comparable to propacetamol and
metamizole, with better safety proﬁle.
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OBJECTIVE: To compare the efﬁcacy and tolerability of dulox-
etine (DLX) with pregabalin (PGB) and gabapentin (GBP) for the
treatment of diabetic peripheral neuropathic pain (DPNP).
METHODS: We searched PubMed, Ovid, CENTRAL databases
and regulatory websites for randomized, double-blind, placebo-
controlled, parallel group or crossover clinical trials (RCTs)
assessing DLX, PGB and GBP in DPNP. Study arms using
approved dosages with assessments after 5–13 weeks were eligi-
ble. Efﬁcacy criteria were: reduction in 24-hour pain severity
(24hPS) for all three drugs, and response rate (>50% pain reduc-
tion) and Patient’s Global Impression of Improvement/Change
(PGI-I/C) for DLX and PGB only. Tolerability criteria were: 
discontinuation, diarrhoea, dizziness, headache, nausea and
somnolence. Pooled ﬁxed- and random-effects analyses were
conducted on endpoints reported in at least two studies of each
drug. Each drug was compared with placebo. DLX was com-
pared indirectly with PGB and GBP by meta-regression.
RESULTS: Three studies of DLX, 6 of PGB and 2 of GBP were
eligible. Between-study heterogeneity was insigniﬁcant. In
random-effects and ﬁxed-effects analyses, all drugs were supe-
rior to placebo for all efﬁcacy parameters, with some tolerabil-
ity trade-offs. Indirect comparison of DLX with PGB found no
differences in 24hPS, but signiﬁcant differences in PGI-I/C,
favouring PGB, and dizziness, favouring DLX were apparent.
Comparing DLX and GBP, there were no statistically signiﬁcant
differences. CONCLUSIONS: From the few studies available for
indirect comparison, DLX shows comparable efﬁcacy and toler-
ability to GBP and PGB in DPNP. Duloxetine provides an impor-
tant treatment option for this disabling condition.
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OBJECTIVES: Comparison of safety of intravenous metamizole,
ketoprofen and paracetamol based on data from WHO Pro-
gramme for International Drug Monitoring. METHODS: The
data from countries participating in the World Health Organi-
zation Programme for International Drug Monitoring are col-
lected and maintained, on behalf of the WHO, by the Uppsala
Monitoring Centre, in the Vigibase. An analysis of data on
adverse events (AE) of intravenous formulations of metamizole,
ketoprofen and paracetamol, reported to Vigibase, from Euro-
pean countries since 1968 up to 29th January 2006 (ref: ER
132/2005), was performed. RESULTS: One thousand three
hundred seventy one individual case reports of metamizole
adverse events were registered in the Vigibase, compared to 367
and 69 for ketoprofen and paracetamol, respectively. Serious AE
were reported in 29 metamizole cases, 47—ketoprofen and none
for paracetamol. There were 15 death cases registered for
metamizole, 1 for ketoprofen and paracetamol. Hematologic dis-
orders were reported in 187 metamizole cases, i.e. 6 and 31 times
more common then for ketoprofen and paracetamol therapy,
respectively. Most frequent AE reports for metamizole were: ana-
phylactic shock (79 cases versus 6 and 3 with ketoprofen and
paracetamol, respectively), agranulocytosis (77 vs 3 vs 1), rash
erythematous (63 vs 26 vs 3), hypotension (54 vs 6 vs 3), pruri-
tus (53 vs 10 vs 1), rash (51 vs 17 vs 0), leucopenia (48 vs 6 vs
2) and circulatory failure (48 vs 5 vs 2). CONCLUSIONS: Intra-
venous therapy with paracetamol is safer than with ketoprofen
or metamizole, concerning total number of reported adverse
events, number of reported serious adverse events and number
of hematologic disorders. Death cases were reported 15 times
more often with metamizole than with either paracetamol or
ketoprofen.
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Chronic lower back pain (CLBP) is a major economic burden on
individuals, health care system and society as a whole. Spinal
fusion surgery is recommended in patients with persistent pain.
Most lumbar spinal fusion surgery involves the use of bone auto-
graft from patient’s iliac crest, which implies increased co-mor-
bidity. InductOs® is indicated for single-level (L4–S1) anterior
lumbar spine fusion as a substitute for autogenous bone graft in
adults with degenerative disc disease (DDD). OBJECTIVE: To
evaluate the potential economic beneﬁts of InductOs® compared
to autograft, in spinal fusions in patients with DDD in Spain.
METHODS: An analytic decision tree model was developed in
order to simulate the clinical pathways of a cohort of 1000 sim-
ulated patients with DDD. The analysis was performed from the
perspective Spanish National Health System (payer), with a time
horizon of 2 years. Clinical and economical data were retrieved
from published studies and ofﬁcial tariffs, validated by a clini-
cian trained in the management of these patients in the Spanish
setting. RESULTS: In Spain, the use of InductOs® leads to a
reduction in operation times and length of stay resulting in
savings of €930 per patient, to a reduction of revisional spinal
procedures resulting in further savings of €428 per patient, and
to a faster return to work by an average of 54 days, resulting in
additional savings of €2304 per patient from sickness-leave pay-
ments avoided. These savings offset the upfront cost of Induc-
tOs® of 2799 resulting in net cost savings of €863 per case
treated, as compared to standard care. CONCLUSION: Adding
